CDKN2A and cancer: To explore the generalizability of our findings, we examined the association between CDKN2A deletion and survival following first-line immunotherapy treatment across various cancer types in CGDB including NSCLC (squamous and non-squamous), melanoma, urothelial cancer, renal cell cancer, head and neck cancer, and gastric cancer.